Bevespi Aerosphere

RSS

glycopyrronium / formoterol fumarate dihydrate

Authorised
This medicine is authorised for use in the European Union.

Overview

Bevespi Aerosphere is a medicine used in adults to relieve the symptoms of chronic obstructive pulmonary disease (COPD). COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing.

Bevespi Aerosphere is used for maintenance (regular) treatment. It contains the active substances glycopyrronium bromide and formoterol.

This EPAR was last updated on 12/05/2022

Authorisation details

Product details
Name
Bevespi Aerosphere
Agency product number
EMEA/H/C/004245
Active substance
  • glycopyrronium
  • formoterol fumarate dihydrate
International non-proprietary name (INN) or common name
  • glycopyrronium
  • formoterol fumarate dihydrate
Therapeutic area (MeSH)
Pulmonary Disease, Chronic Obstructive
Anatomical therapeutic chemical (ATC) code
R03AL07
Publication details
Marketing-authorisation holder
AstraZeneca AB
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
18/12/2018
Contact address

AstraZeneca AB
Sodertalje
SE-151 85 Sodertalje
Sweden

Product information

11/05/2022 Bevespi Aerosphere - EMEA/H/C/004245 - N/0013

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

formoterol and glycopyrronium bromide

Therapeutic indication

Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Assessment history

How useful was this page?

Add your rating
Average
2 ratings
1 rating
1 rating